Shares of small biotech firm Enzon (UNKNOWN:ENZN.DL) were up about 5% today after the CEO announced that Lazard had been hired to look into potentially selling some or all of the company. Carl Icahn, who has a 13% stake in the company, also met with management to discuss something similar; shares have been down since he announced that meeting in late November. In this video, Motley Fool health care analyst David Williamson tells investors what kind of influence we can expect Icahn to have on shares as the company moves toward selling.
Dave Williamson and Max Macaluso
Dec 17, 2012 at 7:12PM
Motley Fool Returns
Stock Advisor S&P 500
5 Years 71% 43%
17+ years 379% 102%
Stock Advisor launched in February of 2002. Returns as of 01/18/2020.Join Stock Advisor